Brain-targeted intranasal delivery of dopamine with borneol and lactoferrin co-modified nanoparticles for treating Parkinson’s disease / Shengnan Tang, Aiping Wang, Xiuju Yan, Liuxiang Chu, Xiucheng Yang, Yina Song, Kaoxiang Sun, Xin Yu, Rongxia Liu, Zimei Wu, Peng Xue
Abstract Efficient delivery of brain-targeted drugs is highly important for successful therapy in Parkinson’s disease (PD). This study was designed to formulate borneol and lactoferrin co-modified nanoparticles (Lf-BNPs) encapsulated dopamine as a novel drug delivery system to achieve maximum therapeutic efficacy and reduce side effects for PD. Dopamine Lf-BNPs were prepared using the double emulsion solvent evaporation method and evaluated for physicochemical and pharmaceutical properties. In vitro cytotoxicity studies indicated that treatment with dopamine Lf-BNPs has relatively low cytotoxicity in SH-SY5Y and 16HBE cells. Qualitative and quantitative cellular uptake experiments indicated that Lf modification of NPs increased cellular uptake of SH-SY5Y cells and 16HBE cells, and borneol modification can promote the cellular uptake of 16HBE. In vivo pharmacokinetic studies indicated that AUC 0–12 h in the rat brain for dopamine Lf-BNPs was significantly higher ( p < .05) than that of dopamine nanoparticles. Intranasal administration of dopamine Lf-BNPs effectively alleviated the 6-hydroxydopamine-induced striatum lesion in rats as indicated by the contralateral rotation behavior test and results for striatal monoamine neurotransmitter content detection. Taken together, intranasal administration of dopamine Lf-BNPs may be an effective drug delivery system for Parkinson’s disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Drug delivery - 26(2019), 1, Seite 700-707 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tang, Shengnan [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Themen: |
Borneol |
|---|
| Umfang: |
1 Online-Ressource (8 p) |
|---|
| doi: |
10.1080/10717544.2019.1636420 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL01119037X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL01119037X | ||
| 003 | DE-627 | ||
| 005 | 20230720210205.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230714s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/10717544.2019.1636420 |2 doi | |
| 035 | |a (DE-627)KFL01119037X | ||
| 035 | |a (KFL)prod_LgpH_10.1080/10717544.2019.1636420 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Tang, Shengnan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Brain-targeted intranasal delivery of dopamine with borneol and lactoferrin co-modified nanoparticles for treating Parkinson’s disease |c Shengnan Tang, Aiping Wang, Xiuju Yan, Liuxiang Chu, Xiucheng Yang, Yina Song, Kaoxiang Sun, Xin Yu, Rongxia Liu, Zimei Wu, Peng Xue |
| 264 | 1 | |c 2019 | |
| 300 | |a 1 Online-Ressource (8 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Efficient delivery of brain-targeted drugs is highly important for successful therapy in Parkinson’s disease (PD). This study was designed to formulate borneol and lactoferrin co-modified nanoparticles (Lf-BNPs) encapsulated dopamine as a novel drug delivery system to achieve maximum therapeutic efficacy and reduce side effects for PD. Dopamine Lf-BNPs were prepared using the double emulsion solvent evaporation method and evaluated for physicochemical and pharmaceutical properties. In vitro cytotoxicity studies indicated that treatment with dopamine Lf-BNPs has relatively low cytotoxicity in SH-SY5Y and 16HBE cells. Qualitative and quantitative cellular uptake experiments indicated that Lf modification of NPs increased cellular uptake of SH-SY5Y cells and 16HBE cells, and borneol modification can promote the cellular uptake of 16HBE. In vivo pharmacokinetic studies indicated that AUC 0–12 h in the rat brain for dopamine Lf-BNPs was significantly higher ( p < .05) than that of dopamine nanoparticles. Intranasal administration of dopamine Lf-BNPs effectively alleviated the 6-hydroxydopamine-induced striatum lesion in rats as indicated by the contralateral rotation behavior test and results for striatal monoamine neurotransmitter content detection. Taken together, intranasal administration of dopamine Lf-BNPs may be an effective drug delivery system for Parkinson’s disease | ||
| 653 | |a Dopamine | ||
| 653 | |a lactoferrin | ||
| 653 | |a borneol | ||
| 653 | |a nose-to-brain targeted nanoparticles | ||
| 653 | |a Parkinson’s disease | ||
| 700 | 1 | |a Wang, Aiping |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Xiuju |e verfasserin |4 aut | |
| 700 | 1 | |a Chu, Liuxiang |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Xiucheng |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Yina |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Kaoxiang |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Rongxia |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Zimei |e verfasserin |4 aut | |
| 700 | 1 | |a Xue, Peng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug delivery |d Abingdon : Taylor & Francis Group, 1993 |g 26(2019), 1, Seite 700-707 |h Online-Ressource |w (DE-627)KFL000005983 |w (DE-600)2020593-4 |w (DE-576)273878719 |x 1521-0464 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2019 |g number:1 |g pages:700-707 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/tandf-ejournals-pharmazie/doi.org/10.1080/10717544.2019.1636420 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-TFE | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_LgpH_02 | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2019 |e 1 |h 700-707 | ||